This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Corticosteroids are a standard first-line treatment for Duchenne muscular dystrophy, but these drugs have many sideeffects. FDA approval of Italfarmaco’s Duvyzat is the first nonsteroidal drug to pass the agency’s regulatory bar for treating this rare disease.
Could cautions about more common sideeffects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro? On Tuesday, the FDA revealed that it is investigating patient reports of suicidal thoughts and hair loss from the use of the blood sugar-modulating products.
But these immunotherapies also come with various potentially dangerous sideeffects. | A new study examined sideeffect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions.
Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for sideeffects—one of them suicide ideation—a study of medi | Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for sideeffects—one (..)
Can diabetes patients really stay adherent to a drug for 63 weeks in which 85% of patients report GI sideeffects and will insurance cover the cost? The headlines read “FDA approves obesity drug that helped people cut weight 15%” But buyer beware.
While GLP-1 drugs from Novo Nordisk and Eli Lilly are believed to be relatively free of serious sideeffects, a few problems have emerged as the treatments have gained wider and longer-term use.
SGAs used to treat bipolar disorder are often effective at helping young patients’ mental health improve but can have significant sideeffects including elevated blood pressure and glucose, increased appetite, as well as weight gain.
So far in August, the FDA has announced two separate drug recalls on its website: one related to particulate concerns and the other thanks to high endotoxin levels. | So far in August, the FDA has announced two separate drug recalls on its website: one related to particulate concerns and the other thanks to high endotoxin levels.
Immunotherapy drugs like teclistamab can result in potentially fatal sideeffects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). In 2022, the drug was approved by the US Food and Drug Administration (FDA) for these patients. We are going with full steam into an era of immunotherapy.”
One agency FDA adviser, resigning from his committee post in protest, called it “probably the worst drug approval decision in recent U.S. Biogen’s Aduhelm won FDA approval after discovering that some patients on higher dosages had displayed improvement of.39 I, therefore, find the FDA’s decision to be puzzling.
Apellis Pharmaceuticals' Syfovre, after achieving the first FDA approval for advanced eye disease geographic atrophy, has been associated with rare but severe sideeffects, according to the America | The American Society of Retinal Specialists sent out a note to doctors on Saturday warning of eye inflammation cases in patients who took Syfovre, (..)
The FDA needs to study what people do when they see a DTC ad. 3hree: DTC marketing minimizes the sideeffects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.” SUMMARY: DTC marketing is not the reason why prescription drugs cost so much.
It’s time to admit that the FDA is completely out of touch regarding DTC advertising. For some reason, the FDA still requires fair balance on website home pages. Fair balance needs to be scraped and the FDA needs to start by asking “what are people looking for when they come to a drug company product website?
Product websites are stagnant, and online health seekers are going elsewhere to learn about your medication’s sideeffects and cost. A website and TV commercials are not enough to get patients to ask for a prescription medication especially when fair balance lists sideeffects like cancer.
GOOD MORNING: The FDA is taking a scientific approach to evaluating direct-to-consumer (DTC) drug advertising, focusing on measuring consumer perceptions of the information presented in ads. What people seem to be interested in are drug sideeffects vs. efficacy. Since when is consumer behavior ever scientific?
While some doctors have been eager to start prescribing the newly approved drug, others had criticized the FDA for clearing the drug before studies proved it works. ” A physician on STAT News wrote, “the consequences of FDA approval are as disturbing as they are vast. Top researchers who advised the U.S. .’s
Don’t just say the “most common sideeffects were.” ” let people know how many people what percentage of people reported certain sideeffects. 8ight: Challenge the FDA. 6ix: P L E A S E address misinformation by providing links to credible health sites.
Biogen undertook a secret campaign, termed Project Onyx, to persuade FDA to approve Aduhelm. As soon as the FDA gave Aduhelm approval, investors rushed to buy Biogen’s stock, and the executive was spreading Kool-aid about the product’s efficacy. Biogen’s reputation may be damaged beyond repair.
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline Biologicals’ Boostrix vaccine for use in pregnant woman in their third trimester, to prevent against whooping cough (pertussis) in infants up to two months of age. However, babies are at highest risk for getting pertussis and having serious complications from it.”.
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. Since that time, Biogen’s MS drugs have faced intense competition as MS patients continue to vent on social media that the Biogen drug has nasty sideeffects. Washington Post.
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new.
“Obesity is multifactorial, meaning many factors are involved and go from genetics, lifestyle, mental health issues (such as trauma) to medication sideeffects,” says Dr. Viana, Clinical Director Yale Medicine Metabolic Health & Weight Loss Program. Many factors contribute to obesity.
The demand quickly exceeded supply after the FDA approved once-weekly semaglutide injections. ” The potential for Wegovy in helping patients lose weight is exciting, but the more people who go on the drug, the higher the sideeffects are going to be. Unfortunately, the hype is going to exceed reality.
The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Like Stelara, the most serious known sideeffect of Wezlana is infection. The post FDA approves first Stelara biosimilar, Wezlana appeared first on European Pharmaceutical Review.
The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. The post FDA rejects Spectrum’s lung cancer drug poziotinib appeared first on.
Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA). The FDA granted the approval of Tzield to Provention Bio.
What are the sideeffects? The FDA can be myopic when researching how consumers view and react to DTC. The FDA should be engaging DTG Research to ask the question, “what are people doing when they are interested in an advertised drug?” That belief is out the window. Is it covered by my insurance?
The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based gene therapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients. Topic sponsors are not involved in the creation of editorial content.
The US Food and Drug Administration (FDA) has granted Leqembi (lecanemab-irmb) Accelerated Approval for Alzheimer’s. The FDA’s decision means the drug is the second of a new category of medications approved for Alzheimer’s that target the fundamental pathophysiology of the disease.
Advertisers want to engage audiences, but at the same time, need to adhere to updated FDA guidance released in November of 2023 for pharmaceutical ads. If an advertiser needs to utilize 60 seconds to meet FDA standards, they face spending double on their media investment versus the cost of a 30-second ad.
To date, there are no US Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. If progress continues in a Phase III clinical trial, this medication would be the first FDA-approved drug specifically for people with notalgia paresthetica. severe itch) in each group.
The FDA’s decision to clear the new indication for the topical JAK1/JAK2 inhibitor came after a priority review that was delayed by a request for additional data by the regulator, holding back a decision by three months. The post FDA clears Incyte’s Opzelura as first vitiligo therapy appeared first on.
The US Food and Drug Administration (FDA) has approved expanded labelling for Cumberland Pharmaceuticals’ Caldolor therapy to include use in infants. Caldolor has already obtained FDA approval for pre-operative administration. Cumberland sponsored a multi-centre trial in 21 hospitalised infants in order to validate its expanded usage.
Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System. “We are pleased that the FDA has recognized the therapeutic potential of the EndoStim System as a new treatment in development for drug refractory GERD,” said Eric Goorno, Chief Executive Officer of EndoStim. .
Santhera should hear from the FDA whether the speedy review has been granted within the next 60 days, and if so the review time will be cut from 10 to six months. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.
Given that most obstructive sleep apnea patients are obese men, it’s dangerous that the sideeffects listed for Sunosi say, “tell your doctor if you have heart problems, high blood pressure, kidney problems, diabetes, or high cholesterol.”
RemeGen has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG). Telitacicept is a proprietary novel fusion protein from RemeGen to treat autoimmune diseases.
In clinical trials, how many people experienced a listed sideeffect? They understand that patient content could be edited to meet FDA requirements, but they like reading others’ experiences managing their health issues. They wanted to know why pharma didn’t communicate that their websites had to meet FDA guidelines?
a China-based pharma company has announced it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical studies of T21, a 3D-printed medicine that can target specific segments in the colon to more safely deliver oral ulcerative colitis (UC) drugs.
The US Food and Drug Administration (FDA) has granted clearance for Neurogene’s investigational new drug (IND) application for NGN-401 to treat Rett syndrome. Neurogene stated that the FDA IND clearance allows it to commence a Phase II/II trial of NGN-401 in female paediatric Rett syndrome patients.
The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals ’ Daybue (trofinetide) to treat Rett syndrome in adult and paediatric patients aged two years and above. Vomiting and diarrhoea are the most common sideeffects observed in the trial.
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. While in the US, the therapy is already being prescribed under an expanded access program , the FDA has requested additional data from a randomised, placebo-controlled trial before it will allow Egetis to schedule a PDUFA date.
Unlike traditional businesses, pharma brands face strict advertising regulations , requiring compliance with FDA guidelines, HIPAA, and Googles healthcare ad policies. Strict ad copy guidelines , including FDA-mandated fair balance requirements. Include safety disclaimers For branded drug ads, always mention risks and sideeffects.
For instance, while patients prioritize benefits and sideeffects, healthcare providers look for clinical evidence and efficacy. FDA Guidelines for DTC Ads: The FDA requires ads to present both benefits and risks equally. What are the FDA requirements for direct-to-consumer ads?
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content